Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004090 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004090: Completed Phase 1 study, sponsored by Northwestern University.
NCT00004090 is a Phase 1 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004090, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of gemcitabine and cisplatin in treating patients who have metastatic or recurrent solid tumors.
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
What the finished NCT00004090 record still lists
NCT00004090 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00004090 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004090 about?
NCT00004090 is a clinical study titled "Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of gemcitabine and cisplatin in treating patients who have metastatic or ...
What is the current status of trial NCT00004090?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00004090?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004090?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia